Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyomavirus large T antigen helicase (LT, LTag)
- Target
- LT, LTag
- Molecular classification
- Helicase (AAA+ ATPase family), Viral oncogene protein, DNA-binding protein, Molecular chaperone, Transcription regulator
01
Overview
Polyomavirus large T antigen helicase is an early-expressed, multi-domain protein essential for the viral lifecycle. It contains a J-domain, intrinsically disordered regions, origin-binding domain, zinc-binding domain, and AAA+ ATPase helicase domain. LT unwinds the circular viral DNA, recruits and manipulates host replication factors, and disrupts cell cycle control by binding tumor suppressors such as p53 and Rb. These actions both facilitate viral replication and drive oncogenic transformation, making large T antigen a paradigm for study in molecular virology and cancer biology. The helicase function involves ATP-dependent conformational changes that melt DNA at the replication origin, with the protein forming hexameric or dodecameric ring structures. LT antigen expression is associated with cellular transformation and neoplasia, and serves as a biomarker in virus-driven tumors and infections.
- Other names
- Large T antigenLTagLTPyV large T antigenSV40 large T antigen
02
Mechanism of action
Inhibitors target the helicase (ATPase) activity, disrupt binding to viral DNA origin, or block interactions with host proteins (p53, Rb, replication machinery)
03
Biological functions
Viral DNA replication (bidirectional unwinding of viral genome)Modulation of cell cycle (induces S phase, interacts with p53, Rb)Transcriptional control (regulates host and viral gene expression)Cell transformation/ImmortalizationRecruitment of host replication machinerySignal transduction (through interactions with cellular pathways)
04
Disease associations
Cancer (due to its transforming/oncogenic properties)Infection (essential for polyomavirus proliferation in host cells)Other (used as a model for studying tumorigenesis and DNA damage response)
05
Safety considerations
Off-target effects due to interactions with host proteins (p53, Rb)Oncogenic transformation if mis-expressedImmortalization of non-cancerous cells in laboratory settings
06
Interacting drugs
No specific approved drugs directly inhibit Polyomavirus large T antigen in clinical practice as of now; research targets include small molecules that disrupt ATPase/helicase function or protein-protein interactions.
07
Biomarkers
Expression of large T antigen itself is a diagnostic and prognostic biomarker in polyomavirus-driven cancers (e.g., Merkel cell carcinoma) and infection
Beyond the preview
Go deeper on Polyomavirus large T antigen helicase (LT, LTag).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polyomavirus large T antigen helicase (LT, LTag).